TEST:

AmoyDx® HRD Complete Panel​

Genomic scar score, given by AmoyDx HRD Complete Panel, was most associated with the efficacy of platinum treatment in patients with high-grade ovarian cancer. Validation is warranted via prospective studies.

"Amoy Diagnostics...announced that the AmoyDx® HRD Complete Panel has been accepted into the Special Review Procedure for Innovative Medical Devices by the China National Medical Products Administration (NMPA). This significant milestone positions the panel as the first domestically developed kit for homologous recombination deficiency (HRD) detection to enter this expedited regulatory pathway. It also marks AmoyDx’s third product to receive the 'Innovative Medical Device' designation, reaffirming our ongoing commitment to delivering cutting-edge solutions in precision oncology."